{
  "docId": "019de074-2806-77f1-979f-2c5838bae35a",
  "docSlug": "7e995254b839b7fbb7e998df4127a7b8",
  "documentTitle": "ATAI | Investor Presentation Deck | 33 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 33,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "Includes a comparison chart of Etifoxine vs Lorazepam and a summary of Phase 1 trial design.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-2806-77f1-979f-2c5838bae35a/22",
  "deckHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a",
  "deckJsonHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a.json",
  "deckAnchorHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.6,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Third Party Study: Non Inferiority Test (Ham-A total score)",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62501387-2031-4ea5-b6dc-fda12817b669",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.6,
        "x": 0.37,
        "y": 0.68
      },
      "kind": "diagram",
      "text": "Completed Phase 1 Trial: Single Ascending Dose and Multiple Ascending Dose",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e405b582-2901-440a-9c43-a004f83b32f3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.37,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Note: HAM-A = Hamilton Anxiety Rating Scale... 1. Ownership... 2. Nguyen et al... 3. Cottin et al...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ffdf3587-92ac-4c62-813f-710d074682bd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.3,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "table",
      "text": "Ownership, Product, Pharmacology, Product Features, Indications, Current Status, Intellectual Property, Highlight",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "48c5b5a0-bf46-45db-9720-0efad28db982",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.37,
        "y": 0.06
      },
      "kind": "title",
      "text": "GRX-917 has the potential for benzodiazepine-like rapid-onset efficacy with improved safety and tolerability",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a64a072-45d4-47f6-afee-289a37561e1d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "SUMMARY",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "253b23df-5b75-4ce7-8e4f-9ef38acfd476",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "0ba7ff11-48ee-48c8-b0a0-2b628306da80",
      "evidence": "The slide title is 'GRX-917 has the potential for benzodiazepine-like rapid-onset efficacy with improved safety and tolerability' and type is 'executive_summary'.",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "executive-summary",
      "slug": null,
      "matchId": "c94e093b-92c2-4d20-874f-7b0d1d7f4ff9",
      "evidence": "Slide provides a high-level overview of the company's lead asset.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}